Skip to main content
All lobbying filings

SPLITOAK STRATEGIES LLC

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Biopharmaceutical company

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Income
$60,000
What the client paid this registrant for the period.
Client based in
Massachusetts

Official filing document

 Lobbyists on this filing 2
  • SARAH KUEHL EGGE
    Previously held: 1998-2000 Legislative Assistant to Senator Bob Kerrey; 2001-2012 Senior Budget Analyst for Senate Budget Committee (Senator Kent Conrad); Fall 2011, Deputy Staff Director, Joint Select Committee on Deficit Reduction
  • AMY JENSEN
    Previously held: 1999-2001 Assistant to the Speaker for Policy; 2003-2005 Special Assistant to the President for Special Affairs

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2

RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; U.S. Competitiveness

FDA modernization

 Bills named in this filing 1
  • H.R. 1672
    Maintaining Investments in New Innovation Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem